Antibody,
nature’s most magnificent molecule, has come of age moving forward from an era
of polyclonal and monoclonal antibodies to its applications as functional antibody
fragments or modifications thereof for developing new
drugs against vexing diseases, such as, cancer and viral infections.
The conventional
therapies against these diseases have not been successful resulting in a shift
towards development of novel antibody-based therapeutics.
The clinical
success of antibodies can be assessed from their major commercial impact as
evidenced by the market for antibody drugs being over $60 billion in 2013,
which is expected to double globally within the decade.
No comments:
Post a Comment